$Nano Labs (NA.US)$ hold, it will close at 8

$Silence Therapeutics (SLN.US)$ Stock rated a buy and with the lowest PT being $31. Had the same dip last year so it will be around February 21 when it reaches its PT.
$Rezolve AI (RZLV.US)$ Alot of short shares sold this month and in September. Reversal should be starting now that it has reached $1.63. First climb will be to 4.70 with that PT being at the end of December. February's PT will be 12.00. Partnerships with Microsoft and Google will push it until they re...

$SKK Holdings (SKK.US)$ What a way to end the day! A day i might add seen a whole lot of great trades! So many that I couldn’t even trade all the one that i or my Brother @Jaguar8 Posted on! But the ones i did catch! Nice! and this one twice now! hehehe

$Zevra Therapeutics (ZVRA.US)$
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics (ZVRA) announces the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C (NPC). The medication is indicated for use with miglustat to treat neurological manifestations in patients 2 years and older. The company reports early adoption exceeding expectat...

$Syndax Pharmaceuticals (SNDX.US)$
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

$Syndax Pharmaceuticals (SNDX.US)$ Reuters· just
FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia With a Kmt2a Translocation